[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatic-surgey\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatic-surgey":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100635899","perioperative-pharmacokineticpharmacodynamic-target-attainment-of-piperacillin-during-major-hepatic-and-pancreatic-surgery-100635899",false,"NCT07558681","Perioperative Pharmacokinetic\u002FPharmacodynamic Target Attainment of Piperacillin During Major Hepatic and Pancreatic Surgery","PROPHTAZ: Evaluation of Pharmacokinetic\u002FPharmacodynamic Target Attainment of Piperacillin During Major Hepatic and Pancreatic Surgery, a Prospective Observational Pharmacokinetic Study","PROPHTAZ","Inclusion Criteria:\n\n* Adults \\> or = to 18 years old\n* Scheduled for major hepatic or pancreatic surgery\n* Receiving piperacillin\u002Ftazobactam as perioperative antibiotic prophylaxis according to guidelines\n\nExclusion Criteria:\n\n* decline to participate\n* Known allergy of beta-lactam","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","OBSERVATIONAL","Hepatic and pancreatic surgeries are associated with a high risk of surgical site infections, particularly in patients with preoperative biliary drainage, which is frequently associated with bacterial colonization of bile. In this context, perioperative antibiotic prophylaxis is essential, and recent guidelines recommend the use of piperacillin\u002Ftazobactam in selected high-risk patients.\n\nHowever, piperacillin, like other β-lactam antibiotics, exhibits pharmacokinetic variability that may be exacerbated during major surgery due to factors such as fluid shifts, hypoalbuminemia, and changes in volume of distribution. These alterations may result in suboptimal antibiotic exposure during the perioperative period, potentially compromising prophylactic efficacy.\n\nDespite these concerns, standard dosing regimens remain unchanged across different types of major abdominal surgery, including hepatic and pancreatic procedures, which differ significantly in terms of duration, physiological impact, and intraoperative management.\n\nThe PROPHTAZ study is a prospective, single-center observational pharmacokinetic study designed to evaluate whether standard perioperative administration of piperacillin\u002Ftazobactam achieves predefined pharmacokinetic\u002Fpharmacodynamic (PK\u002FPD) targets in patients undergoing hepatic or pancreatic surgery. The primary objective is to determine the proportion of patients achieving adequate PK\u002FPD exposure during surgery. Secondary objectives include describing perioperative plasma concentrations, assessing pharmacokinetic variability, identifying factors associated with target non-attainment, and comparing outcomes between surgical subgroups.\n\nThis study aims to provide clinically relevant data to assess the adequacy of current prophylactic dosing strategies and to support potential optimization of antibiotic administration in high-risk surgical patients.",[25,26,27],"Antibiotic Prophylaxis","Pancreatic Surgey","Hepatic Surgery",[29,30,31],"PK\u002FPD target atttainment","piperacillin","surgical site infection","NOT_YET_RECRUITING","2026-04-27",{"date":35,"type":36},"2026-04-30","ACTUAL",{"date":38,"type":21},"2026-05-01",{"date":40,"type":21},"2027-05-01",{"name":42,"class":43},"Central Hospital, Nancy, France","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":70,"leadSponsor":72,"locationsCount":44},"100629789","breath-test-based-assessment-of-sibo-in-chronic-pancreatitis-and-partial-pancreatectomy-100629789","NCT07479238","Breath Test-Based Assessment of SIBO in Chronic Pancreatitis and Partial Pancreatectomy","Prevalence of SIBO in Patients With Chronic Pancreatitis and After Partial Pancreatectomy: Assessment by Glucose, Lactulose and Mixed Triglyceride Breath Tests.","DCP-PCT-EPI","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Ability and willingness to participate in the study and to comply with study procedures\n* Diagnosis of chronic pancreatitis with pancreatic exocrine insufficiency (defined as fecal elastase \\\u003C 200 µg\u002Fg of stool)\n* Ongoing pancreatic enzyme replacement therapy (PERT) with persistent gastrointestinal symptoms (including abdominal pain, dyspepsia, bloating, excessive flatulence, diarrhea, or steatorrhea) or unintentional weight loss ≥ 10% within the previous 6 months despite adequate PERT dosing (≥ 40,000 IU per main meal and half dose for snacks)\n* Patients with ampullary or pancreatic tumors who underwent partial pancreatectomy and subsequently developed pancreatic exocrine insufficiency with persistent gastrointestinal symptoms\n* Indication to undergo glucose, lactulose, and mixed triglyceride breath tests as part of routine clinical practice\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years or \\> 75 years\n* Pancreatic adenocarcinoma or bile duct tumors under active or previous adjuvant therapy\n* Moderate to severe liver disease\n* Severe chronic kidney disease (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²)\n* History of major gastrointestinal surgery, including total pancreatectomy\n* Presence of other active organic gastrointestinal diseases\n* Diabetic gastroparesis\n* Known celiac disease\n* Obstructive jaundice\n* Liver cirrhosis Child-Pugh class C\n* Recent or ongoing infections\n* Severe chronic obstructive pulmonary disease (COPD)\n* Symptomatic thyroid disorders\n* Use of antibiotics, laxatives, probiotics, or prokinetic agents within 4 weeks prior to breath testing\n* Inability or refusal to undergo study procedures\n* Inability or refusal to provide informed consent","75 Years",{"count":55,"type":21},100,"Pancreatic exocrine insufficiency (PEI) results from reduced pancreatic enzyme secretion, leading to malabsorption, malnutrition, and impaired quality of life. Although pancreatic enzyme replacement therapy (PERT) is the standard treatment, some patients remain symptomatic despite apparently adequate therapy. Possible causes include suboptimal dosing or concomitant conditions such as small intestinal bacterial overgrowth (SIBO). This study aims to determine the prevalence of SIBO in symptomatic PEI patients despite adequate PERT and to identify treatable causes of persistent symptoms using non-invasive diagnostic tests, with the goal of improving nutritional status and quality of life.",[58,59,60,26],"SIBO","Pancreatic Insufficiency","Chronic Pancreatitis",[62,63,64,65],"Pancreatic exocrine insufficiency","Chronic pancreatitis","enzyme replacement therapy","Small intestinal bacterial overgrowth","2026-04-09",{"date":68,"type":36},"2026-04-13",{"date":35,"type":21},{"date":71,"type":21},"2028-04-26",{"name":73,"class":43},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS"]